Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC

Yoshihiko Tomita, Sei Naito, Naoto Sassa, Atsushi Takahashi, Tsunenori Kondo, Takuya Koie, Wataru Obara, Yasuyuki Kobayashi, Jun Teishima, Masayuki Takahashi, Hideyasu Matsuyama, Takeshi Ueda, Kenya Yamaguchi, Takeshi Kishida, Ryoichi Shiroki, Takashi Saika, Nobuo Shinohara, Mototsugu Oya, Hiro omi Kanayama

Research output: Contribution to journalArticle

Abstract

The aim of the present randomized controlled study was to compare the efficacy of sunitinib and sorafenib as first-line treatment of patients with metastatic clear cell renal cell carcinoma with favorable or intermediate Memorial Sloan Kettering Cancer Center risk. The median first progression-free survival was 8.7 and 7.0 months in the sunitinib and sorafenib groups, respectively (hazard ratio, 0.67; 95% confidence interval, 0.42-1.08).

Original languageEnglish
JournalClinical Genitourinary Cancer
DOIs
Publication statusAccepted/In press - 2020 Jan 1

Keywords

  • PFS
  • RCT
  • Renal cell carcinoma
  • SO/SU
  • SU/SO

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC'. Together they form a unique fingerprint.

  • Cite this

    Tomita, Y., Naito, S., Sassa, N., Takahashi, A., Kondo, T., Koie, T., Obara, W., Kobayashi, Y., Teishima, J., Takahashi, M., Matsuyama, H., Ueda, T., Yamaguchi, K., Kishida, T., Shiroki, R., Saika, T., Shinohara, N., Oya, M., & Kanayama, H. O. (Accepted/In press). Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2020.01.001